Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 4,249 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Healthy Subjects
Interventions: CKD-508 Tablet, Placebo Tablet; Drug
Lead sponsor: Chong Kun Dang Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more

Conditions: Plaque Psoriasis
Interventions: DSXS, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Ulcerative Colitis
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • Murrieta, California • Clearwater, Florida + 13 more

Conditions: HIV Infections
Interventions: BMS-663068, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 39
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 27 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo; Drug
Lead sponsor: SynAct Pharma Aps; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania

Conditions: Sickle Cell Anemia, Thalassemia
Interventions: L-glutamine, Placebo; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Bellflower, California • Torrance, California • Atlanta, Georgia + 2 more

Conditions: Community Acquired Bacterial Pneumonia
Interventions: Delafloxacin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more

Conditions: Obstructive Sleep Apnea
Interventions: TAK-925, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Cancer Colon
Interventions: blood-based CRC screening; Diagnostic Test
Lead sponsor: Ballad Health; Other
Eligibility: 45 Years to 84 Years
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Insulin Resistance, Mild Cognitive Impairment, Cognitive Decline, Neurodegenerative Disorders
Interventions: Sabroxy®, Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Smoking
Interventions: THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA); Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 22 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions: Study Drug Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Days to 17 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Hypertension
Interventions: Azilsartan Medoxomil and amlodipine, Amlodipine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 50
States / cities: Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more

Conditions: Immunologic Deficiency Syndrome
Interventions: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Birmingham, Alabama • North Palm Beach, Florida • Chicago, Illinois + 5 more

Conditions: Acne Vulgaris
Interventions: Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 14
States / cities: Encino, California • Fremont, California • Brandon, Florida + 8 more

Conditions: Healthy Volunteers
Interventions: IW-3300, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Degenerative Disc Disease, Lumbar Disc Disease, Spine Disease, Lumbar Spine Degeneration
Interventions: LDGraft, Allograft Bone; Device · Other
Lead sponsor: Locate Bio Pty Ltd; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Fort Wayne, Indiana • Pinehurst, North Carolina • Nashville, Tennessee

Conditions: Opioid-Related Disorders, Opiate Dependence
Interventions: Buprenorphine/naloxone sublingual tablets, Buprenorphine; Drug
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Birmingham, Alabama • Haleyville, Alabama • National City, California + 11 more

Conditions: Lice; Head Lice
Interventions: Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Infertility, Poor Ovarian Reserve, Embryo Growth Disorder, in Vitro Fertilization
Interventions: Ovarian Platelet-rich plasma (PRP) injections; Procedure
Lead sponsor: Generation Next Fertility; Other
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Fatigue
Interventions: Energy Active Product, Energy Placebo Control; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Schizophrenia
Interventions: SEP-363856 50mg, SEP-363856 75mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Trial of Reducing Inpatient Antibiotic Durations in Children

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score

Radicle Energy 25: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia